secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2026-03-06T23:59:59+00:00
Accession:  0001213900-26-024752
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed to wind down BayMedica commercial ops; focus shifts to Alzheimer's, AMD pipeline
--------------------------------------------------------------------------------

- Board ratified wind-down of BayMedica commercial operations due to H.R. 5371 uncertainty; completion expected by June 30, 2026.
- Estimated severance costs of ~$550K and other expenses ~$120K; partially offset by product sale profits during wind-down.
- Company will focus exclusively on INM-901 (Alzheimer's) and INM-089 (dry AMD) drug candidates; commercial revenue stream eliminated.
- Pro forma financial statements treat BayMedica as discontinued operations; revenue from commercial ops reduced to $0.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390026024752/0001213900-26-024752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390026024752/ea0279869-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-024752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer